BAYRY - Bayer's US unit BlueRock forms site in Berlin to expand cell therapy program

Bayer's (OTCPK:BAYRY) (OTCPK:BAYZF) Cambridge, Mass.-based subsidiary BlueRock Therapeutics has set up a new site for cell therapy innovation at Bayer's campus in Berlin. The German conglomerate said BlueRock will benefit from the expertise of teams at Bayer to accelerate BlueRock's clinical trials to Europe. BlueRock recently closed enrollment for a phase 1 trial of its cell therapy BRT-DA01 to treat Parkinson's disease, and plans to start a global non-interventional study for patients with Parkinson's in H2 2022, according to Bayer's June 8 press release. The new site expands BlueRock's footprint, with presence in the U.S., Canada, and now in Europe.

For further details see:

Bayer's US unit BlueRock forms site in Berlin to expand cell therapy program